Skip to main content

Rheumatoid Arthritis

      Interesting late breaker!
      Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
      Phase 3

      Robert B Chao, MD

      1 year 10 months ago
      Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression No difference in safety profile compared to placebo @RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
      Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%.

      Richard Conway

      1 year 10 months ago
      Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%. Radiographic benefit also. Safety looks ok. Abstr#L20 #ACR23 #ACRbest @RheumNow https://t.co/qcinGeRX2d https://t.co/SIKKW7xhwV
      Tommasi et al. MTX (vs SSZ) lowers BP in RA in RCT. At 6 months, significant reduction in SBP (mean difference -4.0±10.

      Richard Conway

      1 year 10 months ago
      Tommasi et al. MTX (vs SSZ) lowers BP in RA in RCT. At 6 months, significant reduction in SBP (mean difference -4.0±10.8 mmHg, p=0.038), MAP (mean difference -4.3±17.9 mmHg, p=0.023). Abstr#2151 #ACR23 @RheumNow https://t.co/wAX3dCztxH https://t.co/mPG5TdeHTu
      New MoA in RA 🚨

      Dual inhibition BAFF/BLys Telalicept MTX IR pts Ph3 vs. PBO

      ACR20 60 vs. 27%
      ACR50 21 vs. 6%
      DAS28

      Aurelie Najm

      1 year 10 months ago
      New MoA in RA 🚨 Dual inhibition BAFF/BLys Telalicept MTX IR pts Ph3 vs. PBO ACR20 60 vs. 27% ACR50 21 vs. 6% DAS28<3.2 15 vs. 5% Less Rx prog Safety similar infection rates @RheumNow #ACR23 ABSTL20 https://t.co/WHysLSKyo0
      Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT

      Richard Conway

      1 year 10 months ago
      Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif
      Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was

      Richard Conway

      1 year 10 months ago
      Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE
      Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better

      Richard Conway

      1 year 10 months ago
      Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
      L20 @ #ACR23

      New therapy on the horizon for RA pts that failed MTX?

      ⭐️Telitacicept = recombinant fusion protein ta

      Meral K. El Ramahi, MD MeralElRamahiMD

      1 year 10 months ago
      L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
      Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF
      Identified 7 ab in RD-ILD, emphasizi

      Robert B Chao, MD

      1 year 10 months ago
      Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF Different mechanisms of damage and progression based on ab profile? @RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ
      Daily Recap - TUESDAY
      These year’s annual ACR Convergence has been a success with the return of an insanely active Poster Hall! F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
      For as long as I can remember, methotrexate has been the anchor drug treatment of rheumatoid arthritis. We also know it has limited oral bioavailability at doses greater than 15mg. There are subcutaneous forms that offer better bioavailability, but its subcutaneous nature can sometimes sway patients away from trying it in addition to its higher cost. Split dosing of methotrexate can be a solution to attain higher bioavailability; however, its
      ×